<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="111141">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02154165</url>
  </required_header>
  <id_info>
    <org_study_id>PKV 2013</org_study_id>
    <nct_id>NCT02154165</nct_id>
  </id_info>
  <brief_title>Comparison Between Turquoise and Blue Light in Treatment of Neonatal Jaundice Using Light Emission Diodes</brief_title>
  <official_title>Comparison Between Turquoise and Blue Light in Treatment of Neonatal Jaundice Using Light Emission Diodes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <authority>Denmark: The Regional Committee on Biomedical Research Ethics</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The optimal wavelength for phototherapy for neonatal jaundice remains to be clarified by
      clinical studies. Previous iv vivo studies have shown that turquoise light at wavelength
      about 490 nm is more efficacious than blue light at wavelength 460 nm, which is the golden
      standard in phototherapy treatment today. Though, previous studies used light tubes, today
      we use light emitting diodes (LED'S).

      The overall aim of this study was therefore to compare the efficacy of turquoise LED's
      versus blue LED's for decreasing total serum bilirubin in neonates with gestational age &gt; 33
      weeks and uncomplicated hyperbilirubinemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Decrease in total serum bilirubin</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>The infants were treated with phototherapy for 24 hours, which is the standard treatment.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">90</enrollment>
  <condition>Uncomplicated Neonatal Hyperbilirubinemia</condition>
  <arm_group>
    <arm_group_label>Blue light wavelenght 460 nm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Turquoise light wavelength 499 nm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Phototherapy</intervention_name>
    <description>The infants were randomized to phototherapy with either blue og turquoise light</description>
    <arm_group_label>Blue light wavelenght 460 nm</arm_group_label>
    <arm_group_label>Turquoise light wavelength 499 nm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newborns with gestational age &gt;33 weeks and neonatal hyperbilirubinemia requiring
             treatment with phototherapy according to the national guidelines

        Exclusion Criteria:

          -  Haemolytic disease (Rhesus and Kell blood type isoimmunization,    spherocytosis)

          -  Liver disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>33 Weeks</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Neonatal department, Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>June 2, 2014</lastchanged_date>
  <firstreceived_date>May 30, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Aarhus</investigator_affiliation>
    <investigator_full_name>Helene NÃ¸rrelund</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Neonatal hyperbilirubinemia</keyword>
  <keyword>Phototherapy</keyword>
  <keyword>Light emitting diodes</keyword>
  <keyword>Blue light</keyword>
  <keyword>Turquoise light</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyperbilirubinemia</mesh_term>
    <mesh_term>Jaundice</mesh_term>
    <mesh_term>Jaundice, Neonatal</mesh_term>
    <mesh_term>Hyperbilirubinemia, Neonatal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
